The gastrointestinal hormone, gastric inhibitory polypeptide (GIP), is synt
hesized and released from the duodenum and proximal jejunum postprandially.
Its release depends upon several factors including meal content and pre-ex
isting health status tie. obesity, diabetes, age; etc. It was initially dis
covered and named for its gastric acid inhibitory properties. However, its
more physiologically relevant role appears to be as an insulinotropic agent
with a stimulatory effect on insulin release and synthesis. Accordingly, i
t was later renamed glucose-dependent insulinotropic polypeptide because it
s action on insulin release depends upon an increase in circulating levels
of glucose. GIP is considered to be one of the principle incretin factors o
f the enteroinsular axis. The GIP receptor is a G-protein-coupled receptor
belonging to the family of secretin/VIP receptors. GIP receptor mRNA is wid
ely distributed in peripheral organs, including the pancreas, gut, adipose
tissue; heart, adrenal cortex, and brain, suggesting it may have other func
tions in addition to the ones mentioned above. An overactive enteroinsular
axis has been suggested to play a role in the pathogenesis of diabetes and
obesity. In addition to stimulating insulin release, GIP has been shown to
amplify the effect of insulin on target tissues. In adipose tissue, GIP has
been reported to (1) stimulate fatty acid synthesis, (2) enhance insulin-s
timulated incorporation of fatty acids into triglycerides, (3) increase ins
ulin receptor affinity, and (4) increase sensitivity of insulin-stimulated
glucose transport. In addition, although controversial, lipolytic propertie
s of GIP have been proposed. The mechanism of action of GTP-induced effects
on adipocytes is unknown, and it is unclear whether these effects of GIP o
n adipocytes are direct or indirect. However, there is now evidence that GI
P receptors are expressed on adipocytes and that these receptors respond to
GIP stimulation. Given the location of its release and the timing of its r
elease, GIP is an ideal anabolic agent and expanding our understanding of i
ts physiology will be needed to determine its exact role in the etiology of
diabetes mellitus and obesity.